• Shraddha Balasaheb Amate
• Rohini Suryabhan Dongare
• Tejas Uddhav Amrute

The huge majority of cases reported throughout the world as mucormycosis are infection caused by fungi belonging to the order Mucorales. Cutaneous mucormycosis is increasing fungal contamination because of opportunistic fungi of phylum Glomeromycota. Around 19% of the mucormycosis are cutaneous form and the related mortality of cutaneous mucormycosis occurs about 16%.There are two types of cutaneous mucormycosis first is primary cutaneous mucormycosis (PCM) and second is secondary cutaneous mucormycosis(SCM).Secondary cutaneous mucormycosis is more frequent than primary cutaneous mucormycosis. Most patient with cutaneous mucormycosis have underlying conditions such as diabetes mellitus or solid organ transplantation, haematological malignancies, but a large proportion of them are immunocompetent. After sinusitis and pulmonary cutaneous mucormycosis is the most common clinical presentation. Inadequate production of insulin, Burns or Trauma, Operations, Direct vaccination, Haematological malignancies etc. are the risk factors for cutaneous mucormycosis. Trauma is a critical mode of obtaining the disorder. The disease may be very invasive regionally and penetrate from the cutaneous and subcutaneous tissue into the adjoining fat , muscle, bone and fascia. The prognosis of cutaneous mucormycosis is frequently hard due to the nonspecific findings of the infection. The clinician must have an excessive degree of suspicion and use all available diagnostic tools, because untimely diagnosis leads to an improved outcome. The treatment of cutaneous mucormycosis is multimodal and includes surgical debridement. Antifungal drugs used in cutaneous mucormycosis is Isavuconazole ,Amphotericin B, Posaconazole etc. Posaconazole is the most affective azole with true in-vitro interest towards the Mucorales.

Cutaneous mucormycosis, COVID-19, Mucormycetes, Mucorales, Immunocompetent, Trauma.

"Cutaneous Mucormycosis After COVID-19 Recovery: A Review.", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.8, Issue 10, page no.b25-b31, October-2021, Available :http://www.jetir.org/papers/JETIR2110104.pdf

"Cutaneous Mucormycosis After COVID-19 Recovery: A Review.", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.8, Issue 10, page no. ppb25-b31, October-2021, Available at : http://www.jetir.org/papers/JETIR2110104.pdf